Additionally, predicted MSLN amplifications were found in 9% of the renal cell carcinomas (N = 428 tumors), 5% of the thyroid cancers (N = 21 tumors), 5% of acute myeloid leukemias (N = 761 tumors) and 4% of the HNSCC (N = 356 tumors). This evidence concerns the gene MSLN and acute myeloid leukemia.